Performance Bulletin | Bloomage Biotechnology's Q1 Revenue Reaches 1.078 Billion Yuan, with Strategic Focus on Two Directions: Glycobiology and Cell Biology

On April 25th, Bloomage Biotechnology Corporation Limited disclosed its first-quarter report for 2025. During the reporting period, the company achieved an operating revenue of 1.078 billion yuan and a net profit attributable to shareholders of the listed company of 102 million yuan. In the first quarter of 2025, the revenue increased by approximately 290 million yuan compared with the fourth quarter of 2024. After excluding impairment losses, the company's net profit increased by approximately 180 million yuan compared with the fourth quarter of 2024. During the reporting period, the company's bioactive substances business and medical terminal business remained stable. The R & D, registration, and marketization of new raw materials for bioactive substances and new pipelines for medical terminals accelerated; the innovation and transformation business of skin science was still in the period of reform and adjustment.

In the financial report, this leading enterprise with a 44% global market share in hyaluronic acid raw materials for the first time deeply integrated business adjustment with basic scientific research. Although short - term performance fluctuations have attracted attention, the company emphasized that it is completing a strategic transformation from "concept chasing" to "hard - core breakthrough" - by establishing the core research status of hyaluronic acid and glycobiology in the extracellular matrix (ECM) and cell biology, it will reactivate the multi - billion - level commercial value of hyaluronic acid in the field of cellular anti - aging, which may provide a new paradigm for the transformation of biotech enterprises.